Oral delivery of a therapeutic gene encoding glucagon-like peptide 1 to treat high fat diet-induced diabetes

Nurunnabi, Md; Lee, Seung Ah; Revuri, Vishnu; Hwang, Yong Hwa; Kang, Suk Ho; Lee, Minhyung; Cho, Sungpil; Cho, Kwang Jae; Byun, Youngro; Bae, You Han; Lee, Dong Yun; Lee, Yong kyu

doi:10.1016/j.jconrel.2017.08.035

Cited by 37 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 8 weeks of intervention, the levels of blood glucose were lower and insulin concentration was higher in the Exendin-4/ dsAAV group than in the control group [64]. Different from the above studies, oral administration of the plasmid DNA encoding GLP-1 decreased diabetic glucose levels to the normoglycemic range with significant weight loss [65]. To facilitate oral delivery, the plasmid was conjugated with a nano-sized complex coated with heparin-taurocholic acid (HTCA).…”

Section: Gene Therapy With Glp-1 and Its Analogsmentioning

confidence: 99%

Advances and potential of gene therapy for type 2 diabetes mellitus

Yue

Zhang

et al. 2019

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

Gene therapy of type 2 diabetes mellitus (T2DM) and its complications has attracted intensive interest in recent years. In this paper, we critically review literature reports on gene therapy of T2DM published over the last five years. By reviewing these advances, three questions were addressed. First, which genes and how do they exert anti-diabetic effects? Target genes including that regulating glucose homeostasis, improving insulin secretion or sensitivity, and ameliorating diabetic induced complications are summarized. Second, how to deliver and which route is advantageous? All main methods that have been used for delivery of target genes into diabetic subjects are outlined and discussed regarding their pros and cons. Last, what are the future directions and how do these advances promote the study of T2DM gene therapy? Testing of novel targets in a parallel way and especially, using combinational approaches may be the main directions. In conclusion, there are a large number of genes playing important roles during the incidence and development of T2DM, and many of them hold great promise as potential targets for gene therapy. Oral delivery of target genes by probiotics may be a nice route with priority to develop, due to its high efficiency and safety for future gene therapy of T2DM. ARTICLE HISTORY

show abstract

Section: Gene Therapy With Glp-1 and Its Analogsmentioning

confidence: 99%

Advances and potential of gene therapy for type 2 diabetes mellitus

Yue

Zhang

et al. 2019

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

show abstract

“…Delivery of genetic materials, such as plasmid DNA or siRNA [5–9], as well as combination therapies that deliver both genetic and pharmacological treatments [10], via the oral route, have been explored for the treatment of several diseases. Oral gene delivery has the potential to treat GI tract-specific diseases, such as ulcerative colitis (UC) and cancer, as well as promote systemic therapeutic effects outside of the GI tract, e.g.…”

Section: Oral Gene Delivery For Gene Therapy Applicationsmentioning

confidence: 99%

“…In addition to cell-specific targeting, functionalization of delivery systems with bile acid conjugates has been investigated to enhance gastric stability and improve particle uptake by intestinal enterocytes through bile acid transporters [9]. Investigated as a method to treat type 2 diabetes, Nurunnabi et al developed NPs of DNA and branched poly(ethyleneimine) (bPEI) that were then coated with taurocholic acid-conjugated heparin to improve oral stability and intestinal enterocyte uptake of the NPs.…”

Section: Oral Gene Delivery For Gene Therapy Applicationsmentioning

confidence: 99%

“…Investigated as a method to treat type 2 diabetes, Nurunnabi et al developed NPs of DNA and branched poly(ethyleneimine) (bPEI) that were then coated with taurocholic acid-conjugated heparin to improve oral stability and intestinal enterocyte uptake of the NPs. Oral delivery of these NPs encapsulating DNA encoding glucagon like peptide-1 (GLP-1), a stimulator of insulin secretion by pancreatic cells, was investigated as a therapy for type 2 diabetes [9]. Delivery of a single dose of GLP-1 DNA via oral gavage resulted in maintenance of normal blood glucose levels for 21 days [9].…”

Section: Oral Gene Delivery For Gene Therapy Applicationsmentioning

confidence: 99%

“…Oral delivery of these NPs encapsulating DNA encoding glucagon like peptide-1 (GLP-1), a stimulator of insulin secretion by pancreatic cells, was investigated as a therapy for type 2 diabetes [9]. Delivery of a single dose of GLP-1 DNA via oral gavage resulted in maintenance of normal blood glucose levels for 21 days [9]. Such sustained blood glucose levels suggests a restoration of metabolic homeostasis and indicate that other metabolic diseases (e.g.…”

Section: Oral Gene Delivery For Gene Therapy Applicationsmentioning

confidence: 99%

See 2 more Smart Citations

Oral non-viral gene delivery for applications in DNA vaccination and gene therapy

Farris

Sanderfer

Lampe

et al. 2018

Current Opinion in Biomedical Engineering

View full text Add to dashboard Cite

Non-viral gene delivery via the oral route is a promising strategy for improving outcomes of DNA vaccination and gene therapy applications. Unlike traditional parenteral administration routes, the oral route is a non-invasive approach that lends itself to high patient compliance and ease of dosing. Moreover, oral administration allows for both local and systemic production of therapeutic genes or, in the case of DNA vaccination, mucosal and systemic immunity. However, the oral route presents distinct challenges and barriers to achieving successful gene delivery. Oral non-viral gene delivery systems must be able to survive the harsh and variable environments (e.g. acidic pH, degrading enzymes, mucus layer) encountered during transit through the gastrointestinal tract, while still allowing for efficient transgene production at sites of interest. These barriers present unique design challenges for researchers in material selection and in improving the transfection efficiency of orally delivered genes. This review provides an overview of advancements in the design of oral non-viral gene delivery systems, and highlights recent and important developments towards improving orally delivered genes for applications in gene therapy and DNA vaccination.

show abstract

Nanotechnology‐Mediated Drug Delivery for the Treatment of Obesity and Its Related Comorbidities

Tsou

Wang

et al. 2019

Adv Healthcare Materials

View full text Add to dashboard Cite

Obesity is a serious health issue affecting humanity on a global scale. Recognized by the American Medical Association as a chronic disease, the incidence of obesity continues to grow at an accelerating rate and obesity has become one of the major threats to human health. Excessive weight gain is tied to metabolic syndrome, which is shown to increase the risk of chronic diseases, such as heart disease and type 2 diabetes, taxing an already overburdened healthcare system and increasing mortality worldwide. Available treatments such as bariatric surgery and pharmacotherapy are often accompanied by adverse side effects and poor patient compliance. Nanotechnology, an emerging technology with a wide range of biomedical applications, has provided an unprecedented opportunity to improve the treatment of many diseases, including obesity. This review provides an introduction to obesity and obesity‐related comorbidities. The most recent developments of nanotechnology‐based drug delivery strategies are highlighted and discussed. Additionally, challenges and consideration for the development of nanoformulations with translational potential are discussed. The overall objective of this review is to enhance the understanding of the design and development of nanomedicine for treatments of obesity and related comorbidities.

show abstract

Oral delivery of a therapeutic gene encoding glucagon-like peptide 1 to treat high fat diet-induced diabetes

Cited by 37 publications

References 34 publications

Advances and potential of gene therapy for type 2 diabetes mellitus

Advances and potential of gene therapy for type 2 diabetes mellitus

Oral non-viral gene delivery for applications in DNA vaccination and gene therapy

Nanotechnology‐Mediated Drug Delivery for the Treatment of Obesity and Its Related Comorbidities

Contact Info

Product

Resources

About